Bristol-Myers’ cancer drug Opdivo fuels growth, but revenue falls short
Bristol-Myers Squibb‘s anticoagulant and immunotherapy drugs drove first-quarter revenue growth, but not enough to top expectations. Bristol beat analysts’ earnings estimates but fell short of revenue expectations. The company boosted its full-year forecast. Here’s how […]